secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001104659-25-106664
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q3 net loss $20M; OCU400 Phase 3 nearing completion, Kwangdong deal signed
--------------------------------------------------------------------------------

- Net loss of $20.0M ($0.07/sh) vs $13.0M ($0.05) in Q3 2024; cash $32.9M as of Sep 30 (down from $58.8M Dec 31).
- OCU400 Phase 3 enrollment nearing completion; BLA filing target 1H 2026, top-line data expected 4Q 2026.
- OCU410ST Phase 2/3 trial 50% enrolled; CHMP accepts single US trial for MAA; interim data mid-2026.
- Signed licensing deal with Kwangdong for OCU400 in South Korea; up to $7.5M milestones plus sales milestones and 25% royalties.
- Closed $20M registered direct offering; cash runway into Q2 2026; warrants exercise could add $30M and extend to 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/0001104659-25-106664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925106664/tm2530208d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-106664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer